|
|
Volumn 15, Issue 3, 2010, Pages 84-85
|
|
There is a slight increase in incident diabetes risk with the use of statins, but benefits likely outweigh any adverse effects in those with moderate-to-high cardiovascular risk
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIMETABOLITE;
ATORVASTATIN;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
C REACTIVE PROTEIN;
CHOLESTEROL;
GLUCOSE;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
INSULIN;
LIVER ENZYME;
PLACEBO;
PRAVASTATIN;
ROSUVASTATIN;
SIMVASTATIN;
THIAZIDE DIURETIC AGENT;
BLOOD PRESSURE REGULATION;
BODY MASS;
CARDIOVASCULAR RISK;
CHOLESTEROL SYNTHESIS;
CLINICAL TRIAL;
CONTROLLED STUDY;
DIABETES MELLITUS;
DIABETOGENESIS;
DISEASE ASSOCIATION;
DRUG EFFICACY;
DRUG SAFETY;
FAMILY HISTORY;
FOLLOW UP;
GLUCOSE BLOOD LEVEL;
GLUCOSE TOLERANCE;
GLYCEMIC CONTROL;
HEART INFARCTION;
HEREDITY;
HIGH RISK PATIENT;
HUMAN;
HYDROPHILICITY;
INCIDENCE;
INFLAMMATION;
INSULIN RELEASE;
INSULIN RESISTANCE;
LIPOPHILICITY;
MAJOR CLINICAL STUDY;
META ANALYSIS;
METABOLIC CLEARANCE RATE;
MORTALITY;
MYALGIA;
NOTE;
PRIMARY PREVENTION;
REDUCTION;
SECONDARY PREVENTION;
STROKE;
SYSTEMATIC REVIEW;
UPREGULATION;
|
|
EID: 77953764556
PISSN: 13565524
EISSN: 14736810
Source Type: Journal
DOI: 10.1136/ebm1075 Document Type: Note |
|
Times cited : (7)
|
|
References (4)
|
